We’ve rebranded some of our products, learn more ›
CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.
PhenoCode Signature Virtual Launch Event
The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to select responders that will be critical for the advancement of such treatments. Watch this webcast to learn about spatial signatures, biomarkers based on spatial relationships and protein co-expression on specific cellular subsets that are assessed within the context of the tumor immune microenvironment (TiME), which have demonstrated higher accuracy in predicting response to immunotherapies. Learn from speakers about Akoya’s new multiplex panels based on novel protein chemistry that can accelerate the development of spatial signatures, simplifying the pathway to improved stratification to immunotherapy response.
Attend this webinar to:
- Understand predictive limits of current biomarkers for immunotherapy and the power of protein spatial phenotyping.
- Learn how PhenoCode Signature panels simplifies protein spatial phenotyping and can accelerate spatial signature development.
- Hear how these panel were utilized in a discovery to translational workflow to identify a putative spatial signature.
Video
Speaker
Ning Ma, Ph.D.
Akoya Biosciences
Biography
Yi Zheng, Ph.D.
Akoya Biosciences
Biography
Arutha Kulasinghe, Ph.D.
The University of Queensland
Biography
Arutha Kulasinghe is a Peter Doherty NHMRC Research Fellow and leads the Clinical-oMx Lab at the University of Queensland. Dr Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung cancer, head and neck cancer, and COVID-19.
